Replies to post #58506 on DNAprint Genomics (DNAG)

[johnnyfiber]

Merck Generics has a strong business with excellent leadership and good growth prospects for the future. However it will need continued investment to fully realize its potential and strengthen its market presence,” said Dr. Michael Roemer, Chairman of the Executive Board of Merck KGaA. “In light of the far-reaching changes occurring in the market we are considering as an option the divestiture of Merck Generics to a qualified buyer.”

What are those far reaching changes that you divest yourself of a $280 million dollar business?



Irrespective of this strategic evaluation Merck still plans to make a capital increase of EUR 2 billion to EUR 2.5 billion within the first quarter of 2007.

Where's that cash goin'? Gimme some'a dat! JMHO